Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-08-17

Clinical Trial Update: Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating evening dosing of indacaterol in patients with chronic obstructive pulmonary disease has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Indacaterol (indacaterol)

Snippet

Sponsor: Novartis | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2011-08-17